Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz et al.
Research Article — Peer-Reviewed Source
Original research published by Holman et al. in New England Journal of Medicine. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .).
Full text is available at the publisher.
Read at Publisher| DOI | 10.1056/nejmoa1612917 |
| Journal | New England Journal of Medicine |
| Year | 2017 |
| Authors | Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C.N. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez |
| License | Open Access — see publisher for license terms |
| Citations | 2,102 |